The aim of this report is to assess the added benefit of vandetanib compared to best supportive care (BSC) as appropriate comparator therapy (ACT) in patients with aggressive and symptomatic medullary thyroid carcinoma (MTC) with unresectable, locally advanced or metastatic disease.
http://ift.tt/2t20Sb9
Τετάρτη 14 Ιουνίου 2017
Vandetanib -- Re-assessment of Benefit According to §35a, Paragraph 5b, Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου